|
Ipsen - Company Profile Snapshot
| Company Profile: |
Ipsen |
| Ticker: |
IPN |
| Exchanges: |
PAR |
| 2008 Sales: |
971,020,000 |
| Major Industry: |
Drugs, Cosmetics & Health Care |
| Sub Industry: |
Ethical Drug Manufacturers |
| Country: |
FRANCE |
| Employees: |
4277 |
Business Description
Ipsen. The Group's principal activity is to develop and distribute pharmaceutical products. The Group develops innovative drugs used in therapeutic areas in oncology, endocrinology and neuromuscular disorders. Some of their products include Decapeptyl, Somatuline, NutropinAq, Autogel, Forlax, Tanakan, Testim and Dysport. The Group also offers products on primary care which includes the areas of gastroenterology, cardiovascular and cognitive disorders. The Group operates throughout the world, In 2008, the Group acquired Vernalis Pharmaceuticals and Tercica Inc.
|
Not the Report you are looking for?
Click here for more browsing options.
|
The following information is available to subscribers or can be accessed by purchasing the Company Profile Report:
|
- Address (mailing), Phone Number, Web Address
- Earnings/Dividends
- Employees
- Exchanges Listed
- Financial Ratio Analysis |
- Recent Stock Performance
- Sales (recent year)
- Senior Officers
- Shareholder Information
- Stock Analysis Summary |
Layout and Content of a Typical Report
|
|
|
|
|
